- Home
- RCG vs BLRX Comparison
RCG vs BLRX Comparison
Compare RCG & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCG
- BLRX
- Stock Information
- Founded
- RCG 1994
- BLRX 2003
- Country
- RCG United States
- BLRX Israel
- Employees
- RCG N/A
- BLRX N/A
- Industry
- RCG Investment Managers
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RCG Finance
- BLRX Health Care
- Exchange
- RCG Nasdaq
- BLRX Nasdaq
- Market Cap
- RCG 15.6M
- BLRX 17.3M
- IPO Year
- RCG N/A
- BLRX 2011
- Fundamental
- Price
- RCG $2.87
- BLRX $0.11
- Analyst Decision
- RCG
- BLRX Strong Buy
- Analyst Count
- RCG 0
- BLRX 2
- Target Price
- RCG N/A
- BLRX $5.50
- AVG Volume (30 Days)
- RCG 5.9K
- BLRX 19.2M
- Earning Date
- RCG 01-01-0001
- BLRX 11-25-2024
- Dividend Yield
- RCG 0.98%
- BLRX N/A
- EPS Growth
- RCG N/A
- BLRX N/A
- EPS
- RCG N/A
- BLRX N/A
- Revenue
- RCG N/A
- BLRX $21,991,000.00
- Revenue This Year
- RCG N/A
- BLRX N/A
- Revenue Next Year
- RCG N/A
- BLRX N/A
- P/E Ratio
- RCG N/A
- BLRX N/A
- Revenue Growth
- RCG N/A
- BLRX N/A
- 52 Week Low
- RCG $1.52
- BLRX $0.08
- 52 Week High
- RCG $1.90
- BLRX $1.44
- Technical
- Relative Strength Index (RSI)
- RCG 65.66
- BLRX 30.38
- Support Level
- RCG $2.32
- BLRX $0.08
- Resistance Level
- RCG $2.58
- BLRX $0.14
- Average True Range (ATR)
- RCG 0.12
- BLRX 0.03
- MACD
- RCG 0.04
- BLRX -0.00
- Stochastic Oscillator
- RCG 100.00
- BLRX 7.14
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, Oil and Gas, medical chemicals, botanical products, and others.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.